Pharma manufacturing news in brief
pharmafile | February 13, 2012 | News story | Manufacturing and Production |Â Â Bosch, Lilly/Bend Research, Neuland, OctoPlus Ferring and CHEMO Particle SciencesÂ
Neuland posts revenue gains, Bosch buys Eisi machinery, plus deals for Lilly/Bend Research, OctoPlus/Ferring and CHEMO/Particle Sciences.
India’s Neuland Laboratories has posted fiscal third-quarter revenues of $21.6 million, up 14% year-on-year, thanks to “gains in sales of the company’s products and services from its active pharmaceutical ingredient (API), contract research and manufacturing and peptides synthesis businesses”. Operating profit came in at $1.85 million, down from $2.19 a year ago because of higher materials and labour costs. The company says it is considering a rights issue to help raise capital.
Eli Lilly has licensed a proprietary spray-dried dispersion technology used to improve the bioavailability of poorly-soluble compounds from formulation and drug delivery specialist Bend Research. Lilly will also have broad access to Bend Research’s portfolio of other drug-delivery technologies under the terms of the deal, and the letter firm will continue to provide formulation, development, analytical, engineering and manufacturing services to Lilly to support its pre-clinical and clinical development programmes.
Bosch Packaging Technology has entered an agreement to acquire Eisai’s machinery business, which specialises in inspection systems for liquid pharmaceuticals such as ampoules, pre-filled syringes, infusion bottles or vials, as well as for solid-dose formulations. The company generated sales of around $103 million in 2010 and has 120 associates worldwide with locations and service centres in Japan, Germany, North America, and China. Financial details were not disclosed.
Spain-headquartered contract manufacturer CHEMO has teamed up with US contract research organisation Particle Sciences to offer development and commercial manufacturing services for hormone-eluting medical devices. The two firms have been working together for several years on a number of combination hormone-based products, and have decided to offer a complete development and manufacturing service to other companies. Under the agreement, Particle Sciences will do the development work and produce initial clinical trial materials (CTM), while CHEMO will take over production from mid- to late-stage clinical testing through to marketing.
Netherlands-based OctoPlus has signed a formulation development and manufacturing contract with Switzerland’s Ferring Pharmaceuticals. The contract is expected to make a material contribution to OctoPlus’ 2012 revenues, according to the company, although it did not disclose any other financial details. OctoPlus’ portfolio includes delivery systems for both small- and large-molecule drugs.
Phil Taylor
Related Content
Bosch gets bigger in India; unveils new capsule filler
Bosch Packaging Technology has expanded its presence in India with the opening of a new …
Bosch planning second packaging plant in China
Bosch Packaging Technology has decided to boost its presence in Asia with the construction of …
Bosch boosts pharma processing ops with Oystar purchases
Bosch Packaging Technology is planning to expand its position in the pharmaceutical processing equipment sector …
